Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

9.090 -0.110 (-1.20%)
Streaming Delayed Price Updated: 9:32 AM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
News headline image
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Second Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Second Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
From Personalis, Inc.
Via Business Wire
News headline image
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
From Personalis, Inc.
Via Business Wire
News headline image
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.